

Aus der Augenklinik und Poliklinik  
Klinik der Ludwig-Maximilians-Universität München  
Direktor: Prof. Dr. med. Siegfried G. Priglinger

**Combined inhibition of  
vascular endothelial growth factor (VEGF) and  
platelet derived growth factor (PDGF)  
for neovascular AMD *in vitro***

Dissertation  
zum Erwerb des Doktorgrades der Medizin  
an der Medizinischen Fakultät der  
Ludwig-Maximilians-Universität zu München

vorgelegt von  
Jakob Georg Siedlecki  
aus Augsburg

2019

Mit Genehmigung der  
Medizinischen Fakultät  
der Universität München

Berichterstatterin: Prof. Dr. med. K. Eibl-Lindner

Mitberichterstatter: Prof. Dr. med. C.-L. Schönfeld  
PD Dr. med. C.-A. Lackerbauer  
PD Dr. rer. nat. H. Mannell

Mitbetreuung durch den  
promovierten Mitarbeiter: Dr. med. C. Wertheimer

Dekan: Prof. Dr. med. dent. Reinhard  
Hickel

Tag der mündlichen Prüfung: 23.05.2019

**Gewidmet meinen Eltern  
in Dankbarkeit**

## AFFIDAVIT

I hereby confirm that this thesis, entitled

**„Combined Inhibition of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) for neovascular AMD *in vitro*“,**

is my own unaided work. Moreover, I confirm that no sources other than the ones indicated in the thesis itself have been used. All direct or indirect sources used are acknowledged as references.

Neither in exactly this, nor in a similar version has this work been previously submitted to any other examining body.

Munich, 28th of May 2019

---

Place, Date

Jakob Siedlecki

---

Signature of doctoral candidate

## TABLE OF CONTENTS

<b><u>1</u></b>	<b><u>ABBREVIATIONS</u></b>	<b><u>6</u></b>
<b><u>2</u></b>	<b><u>CONFIRMATION OF CO-AUTHORS</u></b>	<b><u>7</u></b>
<b><u>3</u></b>	<b><u>INTRODUCTION</u></b>	<b><u>10</u></b>
<b><u>4</u></b>	<b><u>SUMMARY</u></b>	<b><u>16</u></b>
<b><u>5</u></b>	<b><u>ZUSAMMENFASSUNG (DEUTSCHE VERSION)</u></b>	<b><u>20</u></b>
<b><u>6</u></b>	<b><u>PUBLICATIONS RESULTING FROM THIS THESIS</u></b>	<b><u>24</u></b>
<b><u>7</u></b>	<b><u>REFERENCES</u></b>	<b><u>26</u></b>
<b><u>8</u></b>	<b><u>ACKNOWLEDGMENT</u></b>	<b><u>32</u></b>
<b><u>9</u></b>	<b><u>CURRICULUM VITAE</u></b>	<b><u>33</u></b>
<b><u>10</u></b>	<b><u>PUBLICATION LIST</u></b>	<b><u>35</u></b>

## 1 Abbreviations

AMD	age-related macular degeneration
CNV	choroidal neovascularization
CTGF	connective tissue growth factor
DMSO	dimethyl-sulfoxide
EMA	European Medicines Agency
ETDRS	early treatment of diabetic retinopathy study
FDA	US Food and Drug Administration
GA	geographic atrophy
hPC-PL	human pericytes from placenta
HUVEC	human umbilical vein endothelial cells
IC <sub>50</sub>	half-maximal inhibitory concentration
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
nAMD	neovascular age-related macular degeneration
OCT	optical coherence tomography
PI3K	phosphoinositide 3-kinase
PCR	polymerase chain reaction
PLC- $\gamma$	phospholipase $\gamma$
PIGF	placental growth factor
PDGF	platelet derived growth factor
PRN	pro re nata
MAPK	mitogen activated protein kinase
RNA	ribonucleic acid
RPE	retinal pigment epithelium
SMA	smooth muscle actin
XTT	2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2 <i>H</i> -Tetrazolium-5-Carboxanilide
VEGF	vascular endothelial growth factor

## **2 Confirmation of co-authors**

Confirmation pursuant to § 4a Paras. 3 and 5 Doctoral Degree Regulations for Dr. med., Dr. med. dent. and Dr. rer. biol. hum. and pursuant to § 7 Para. 4 Doctoral Degree Regulations for Dr. rer. nat. at the Medical Faculty.

Author contributions are classified according to the International Committee of Medical Journal Editors (ICMJE) author criteria:

- (1) Substantial contributions to the conception or design of the work OR
- (2) The acquisition, analysis, or interpretation of data for the work; AND
- (3) Drafting the work or revising it critically for important intellectual content; AND
- (4) Final approval of the version to be published; AND
- (5) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

- I) Siedlecki J, Wertheimer C, Wolf A, Liegl R, Priglinger C, Priglinger S, Eibl-Lindner, K. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2017;255(5):963-972

I hereby confirm that the article mentioned above, submitted for this doctoral degree, has not been the subject of another (current or completed) dissertation.

---

Signature of doctoral candidate

By signing, the following **co-authors** confirm:

- the extent of their contributions in the publications submitted,
- their agreement to the submission of the publications, and
- that the article in question is not the subject of another (current or completed) dissertation.

Name of co-author	ICMJE author contribution	Signature
Christian Wertheimer	1-5	_____
Armin Wolf	1-5	_____
Raffael Liegl	2-5	_____
Claudia Priglinger	1-5	_____
Siegfried Priglinger	2-5	_____
Kirsten Eibl-Lindner	1-5	_____



- II) Siedlecki J, Asani B, Wertheimer C, Hillenmayer A, Ohlmann A, Priglinger C, Priglinger S, Wolf A, Eibl-Lindner K. Combined VEGF/PDGF inhibition using axitinib induces alphaSMA expression and a pro-fibrotic phenotype in human pericytes. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2018;256(6):1141-1149

I hereby confirm that the article mentioned above, submitted for this doctoral degree, has not been the subject of another (current or completed) dissertation.

---

Signature of doctoral candidate

By signing, the following **co-authors** confirm:

- the extent of their contributions in the publications submitted,
- their agreement to the submission of the publications, and
- that the article in question is not the subject of another (current or completed) dissertation.

Name of co-author	ICMJE author contribution	Signature
Ben Asani	1-5	_____
Christian Wertheimer	1-5	_____
Anna Hillenmayer	2-5	_____
Andreas Ohlmann	1-5	_____
Claudia Priglinger	1-5	_____
Siegfried Priglinger	2-5	_____
Armin Wolf	1-5	_____
Kirsten Eibl-Lindner	1-5	_____

### **3 Introduction**

The scope of diseases affecting the macula is broad. As this special region provides the highest visual acuity of the retina, it has specific metabolic needs, especially in its central part, the fovea<sup>1</sup>. The retinal pigment epithelium (RPE), which provides metabolic support to the outer retina, has its highest RPE to photoreceptor density subfoveally<sup>2</sup>, and also choroidal thickness has been found to be highest in the foveolar region<sup>3-5</sup>.

Due to these support mechanisms, aging of the healthy human retina, measured as photoreceptor loss, is paradoxically less pronounced in the fovea and parafoveal area than in the retinal periphery<sup>6,7</sup>. Conversely, in the case of decompensation of these support mechanisms, macular degeneration can cause rapid and severe loss of visual acuity<sup>8</sup>.

Age-related macular degeneration (AMD) is the most frequent cause of irreversible visual impairment and blindness in the elderly<sup>9,10</sup>, affecting 8.7% of the world population between 45 and 85 years<sup>11</sup>. Due to demographic change, the number of people affected is expected to increase 1.5-fold within 20 years from 2020, equalling 288 million by 2040<sup>11</sup>.

Clinically, AMD is defined by the accumulation of Drusen  $\geq 63 \mu\text{m}$  on OCT imaging of the macula<sup>12</sup>. Drusen mainly contain lipid<sup>13</sup> and seem to represent unprocessed debris of the visual cycle<sup>14</sup>. Following Drusen growth and accumulation, AMD progresses via the intermediate into the late stage, which is defined (I) as the 'wet' form characterized by the development of pathologic vessels growing from the choroid into the neuroretina, termed choroidal neovascularization (CNV); or (II) the 'dry' form, characterized by progressive atrophy of the retinal pigment epithelium, photoreceptors and choriocapillaris, termed geographic atrophy (GA)<sup>8,15</sup>.

Visual decline is much more rapid and severe in the 'wet' compared to the 'dry' phenotype<sup>8,16</sup>. While the wet form makes up 10 to 15 % of all cases of AMD, it is responsible for severe visual disability in about 80 % of AMD patients. This is due to the results of pathologic angiogenesis as represented in CNV: fibrovascular disruption of the neuroretina, leakage of fluid and bleeding<sup>17</sup>. Therefore, management of AMD in its neovascular phenotype mainly represents the management of pathologic angiogenesis, i.e. the re-induction of vascular quiescence, the promotion of regression of pathologic vessels, and the prevention of vessel regrowth<sup>8</sup>. With the advent of Verteporfin photodynamic therapy in 1999, the risk of moderate and severe vision loss

secondary to neovascular AMD (nAMD) could be significantly diminished compared to the natural course, however not offering mean gains in mean visual acuity compared to baseline<sup>18,19</sup>. In 2006, the advent of the first intravitreal anti-VEGF antibody Ranibizumab (Novartis AG, Basel, Switzerland) revolutionized the treatment of nAMD, for the first time offering partial restoration of visual acuity lost due to neovascular disease during a follow-up of two years<sup>20,21</sup>. In the following, non-inferior clinical outcomes were also demonstrated for the antibody Bevacizumab, of which Ranibizumab is a fragment, during a follow-up of 5 years<sup>22</sup>.

After a ten-year experience with anti-VEGF, two major limitations have however proven challenging in clinical practice. Firstly, the currently available anti-VEGF substances have to be re-injected frequently due to the chronicity of the disease and several mechanisms of drug clearance from the vitreous body<sup>23-25</sup>. In the pivotal phase three studies, Ranibizumab was therefore injected on a fixed interval of four weeks<sup>20,21</sup>, which is difficult to translate into clinical practice due to the burden on patients and health care providers alike, resulting in inconsistent reinjections and frequent discontinuation of therapy in real life<sup>26</sup>. According to current guidelines, in the case of newly diagnosed nAMD, an upload of three injections every four weeks is recommended and has been widely adopted worldwide<sup>8,27</sup>. While there is much consensus on this 'induction phase', intensity of treatment in the following 'maintenance phase' has been highly debated<sup>28,29</sup>. In the beginning of anti-VEGF therapy, clinicians adopted a pro re nata (PRN) regimen, which, after the upload, moves to monthly monitoring and further treatment in the case of documented loss of visual acuity or OCT showing signs of disease reactivation, defined as re-injection criteria as proposed in the PrONTO study<sup>30</sup>. Experience gained in the following years however showed that (I) reactivation of CNV and recurrence of macular fluid is significantly associated with increased short and long-term loss of visual acuity<sup>31</sup>; and (II) that disease activity and thus intensity of therapy needed are highly individual<sup>30,32</sup>. Therefore, nowadays a 'treat & extend' regimen is recommended, which aims at individualizing treatment intervals and reducing control and injection visits while preventing recurrence of edema<sup>28,29</sup>. After an upload of three injections every four weeks, injections are performed at every follow-up visit, but treatment intervals are extended by two weeks in the case of successful disease management, i.e. no signs of macular fluid or CNV reactivation on OCT imaging. In the case of disease reactivation, e.g. recurrence of macular fluid on OCT, the treatment interval is

shortened by two weeks (minimum: 4 weeks). After achieving an interval of 12 weeks, anti-VEGF therapy might be considered to be stopped or, as disease reactivation is frequent, paused<sup>28,29</sup>.

Although the treat & extend regimen allows for a reduction of control and injection visits and has been shown to obtain superior results to PRN injections<sup>27</sup>, repeated need of diagnostic and therapeutic interventions over many years poses a gigantic socioeconomic burden<sup>33,34</sup>. Further development of anti-VEGF substances has therefore aimed at improved and prolonged anti-neovascular activity; in 2012, bimonthly intravitreal Aflibercept was shown to be non-inferior to monthly Ranibizumab treatment, as second substance gaining approval for the treatment of nAMD<sup>35,36</sup>. However, differences in injection rates and socioeconomic cost between Ranibizumab and Aflibercept are of little clinical significance<sup>34,37</sup>, with 4.9 (Ranibizumab) vs. 5.2 (Aflibercept) injections in the first year, as reported in the US<sup>37</sup> or by preliminary data of the RIVAL trial (ongoing).

Secondly, in addition to the high intensity of treatment, mean long-term visual acuity results in nAMD are poor in spite of anti-VEGF therapy. Data from the Seven-Up trial, for the first time offering substantial follow-up beyond two years and indicating a mean loss of 8.2 ETDRS letters after seven years<sup>33</sup>, was recently confirmed by the five-year results of the comparison of age-related macular degeneration treatment trials (CATT), which indicate a mean loss of 10.8 letters in comparison to the gains at year two<sup>33</sup>. In addition to this mean loss in visual acuity, about ten percent of patients are classified as anti-VEGF non-responders, losing more than 15 ETDRS letters at two years<sup>20,28,38</sup>. Both the high intensity of treatment, caused by repeated CNV reactivation, as well as the poor long-term outcomes, which are clearly attributed to the presence of intraregional fluid, scarring and atrophy, are signs of not sufficiently managed CNV activity<sup>31</sup>. Therefore, the evaluation of new therapy strategies for nAMD is of great interest, aiming at improving long-term visual outcome, and secondly lowering the treatment burden for patients and health care professionals alike.

In addition to VEGF, a variety of growth factors has been shown to play a major role in nAMD, including platelet derived growth factor (PDGF), placenta growth factor (PIGF) and connective tissue growth factor (CTGF), among others<sup>39</sup>. Of these, the combined inhibition of VEGF and PDGF has been studied most extensively in *in vitro* and *in vivo* oncologic and ophthalmologic studies<sup>40-42</sup>. The interaction between these two growth factors is highly dependent on the vascular status, as quiescent vessels have other

metabolic needs than vessels involved in angiogenesis and vascular remodeling<sup>43</sup>. While physiological vascular quiescence is mediated by simultaneous, concerted VEGF/PDGF action, angiogenesis in health and disease requires sequential growth factor signalling, as it is a result of firstly vessel formation (mediated by endothelial cells and VEGF) and secondly vessel maturation (mediated by cells of the vascular wall, mainly pericytes and PDGF)<sup>43,44</sup>.

Vessel formation in CNV is a result of *sprouting angiogenesis*, which can be divided into four steps<sup>45</sup>. Firstly, endothelial cells loosen their intercellular contacts and secrete matrix metalloproteinases, releasing themselves and cells of the vascular wall from the basement membrane<sup>45</sup>. Secondly, endothelial cells migrate into the interstitium<sup>45</sup>. While so-called *tip cells* lead the vascular sprout, their release of VEGF directed backwards causes so-called *stalk cells* to follow<sup>46</sup>. In the third step, the cells proliferate, finally resulting in the formation of tube-like structures, after which the establishment of a new basement membrane follows in the fourth step<sup>45</sup>. All of these mechanisms are mainly VEGF-dependent, and current anti-neovascular therapy is believed to convey its therapeutic properties by the interference with them, reducing vascular leakage and thus retinal edema, inducing partial vessel regression, and delaying CNV regrowth<sup>47</sup>.

After these VEGF-driven steps representing vessel formation, PDGF driven vessel maturation establishing stable vascular constructs and endothelial cell VEGF independence is mediated by the recruitment of pericytes and smooth muscle cells<sup>44</sup>. Pericytes mediate this maturation by mechanical stabilization and the paracrine secretion of endothelial cell supporting growth factors, mainly Angiopoietin 1 and VEGF<sup>48</sup>. As pericyte-derived VEGF is secreted in an iuxtacrine/paracrine fashion, common intravitreal anti-VEGF neutralization cannot sufficiently exert inhibitory effects in this case<sup>49,50</sup>. Pericytes themselves are VEGF-independent<sup>44</sup>. Thus, pericyte covered segments of CNV are supposed to be partially anti-VEGF resistant, rendering a substantial percentage of the CNV irresponsible to nowadays' standard of care<sup>51</sup>. This is supported by ongoing OCT angiography studies, as for the first time reported by Huang et al.<sup>47</sup>, which show that CNV size can be reduced by anti-VEGF, but CNV cannot be forced into complete regression, and that regrowth from persisting vascular beds re-occurs as anti-VEGF levels drop with time. To start angiogenesis, hypoxic regions of the retina release VEGF, inducing excess formation of new vessels. As reported for the first time by Benjamin et al.<sup>52</sup>, pericyte recruitment and association with

newly formed vessels then lag a few days behind. This opens a plasticity window for vascular remodelling, as pericyte-naïve tubes are forced into regression when anti-VEGF levels drop because the newly vascularized retina is not hypoxic anymore<sup>52</sup>. Only larger vascular trunks, having undergone pericyte coverage, then persist in spite of VEGF depletion, and form the new vascular bed<sup>43</sup>.

Blockage of the PDGF pathway can disrupt endothelial cell-pericyte communication<sup>40</sup>. In this way, addition of anti-PDGF substances to the arsenal against nAMD might interfere with pericyte recruitment to neovessels, and secondly probably strip pericytes off matured CNV segments. This provides a very interesting new strategy to manage CNV in AMD, as exposing a more vulnerable pericyte-naïve CNV to anti-VEGF would improve neovascular management<sup>44</sup>.

The PDGF family consists of five polypeptides of 30 kilodalton (kDa)<sup>53</sup>. Signaling is mediated in a dimerized fashion, resulting in the subforms PDGF-AA, -BB, -CC, -DD and the mixed form -AB<sup>53</sup>. In the eye, signaling is predominantly mediated by PDGF-BB<sup>54-56</sup>. Large global, multicenter, randomized, prospective, double-masked, controlled superiority trials have been designed to study the effect of combined anti-VEGF and anti-PDGF-BB inhibition on nAMD<sup>41,42</sup>. Combined with Ranibizumab or Aflibercept treatment, PDGF inhibition was achieved by the additional intravitreal injection of Pegpleranib (Fovista; Ophtotech, New York USA), an aptamer designed to bind PDGF-BB<sup>41,42</sup>. Published data from the phase IIb trial showed promising results with 62% visual gain in the combination arm (1.5 mg Pegpleranib) compared to Ranibizumab mono, translating into 10.6 vs. 6.5 early treatment of diabetic retinopathy study (ETDRS) letters after 24 weeks<sup>41</sup>. However, the following phase III study failed to confirm superiority<sup>57</sup>. Additionally, the sequential injection of both agents at a volume of 0.05 ml in the same visit, equaling twice the volume of nowadays standard of care, required thorough post-interventional monitoring of intraocular pressure in all study patients and IOP-lowering therapy in some (own experience).

The first anti-VEGF substance to enter the clinic was the aptamer Pegaptanib in 2004 (Macugen; EyeTech Pharmaceuticals, New York, USA)<sup>58</sup>. However, the later antibodies Ranibizumab and Aflibercept have been shown to be of greater potency in suppressing nAMD<sup>59,60</sup>. In a similar fashion, PDGF suppression in pericytes has been shown to be of high anti-neovascular effect *in vitro* and *in vivo*<sup>40,61</sup>, but might not be thoroughly addressed by the aptamer Pegpleranib in humans *in vivo*. This is supported by the fact that PDGF, supporting pericyte coverage of neovessels, is secreted as

growth factor in a paracrine fashion and bound to heparan sulfate proteoglycans on the endothelial surface or in the matrix surrounding pericytes, thus being less exposed to neutralization by aptamers or antibodies in the vitreous body<sup>62</sup>.

An alternative option to modulate growth factor signaling is to inhibit the growth factor's receptor to prevent the intracellular downstream cascade, a principle which should not be affected by paracrine secretion or heparan sulfate proteoglycan binding<sup>63-65</sup>. Biochemically, VEGF and PDGF, as well as their receptors, share major ultrastructural similarities going so far that VEGF-A has been shown to be able to signal via PDGF receptors in mesenchymal stem cells<sup>66</sup>. Therefore, many tyrosine kinase inhibitors simultaneously modulating VEGF- and PDGF-receptor signaling are available<sup>67</sup>. For the experimental anti-VEGF/PDGF inhibition reported in Publication I and II herein, the tyrosine kinase inhibitor Axitinib (Inlyta; Pfizer, New York, USA) was chosen as it features the lowest half-maximal inhibitory concentration (IC<sub>50</sub>) for VEGF receptors 1, 2 and 3 (0.1 – 0.3 nM) and PDGFR-ββ (1.6 nM) of all anti-VEGF/PDGF tyrosine kinase inhibitors available clinically; moreover, good biocompatibility with ocular tissue is suggesting it for intravitreal use<sup>67</sup>. While Axitinib also inhibits c-KIT, these effects on pericytes can be neglected as pericytes do not express c-KIT<sup>68</sup>. Axitinib has been approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma in 2012<sup>69</sup>.

Publication I entitled “*Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro*” seeks to answer the question whether VEGF/PDGF-receptor inhibition using Axitinib poses a feasible alternative method of anti-angiogenesis against both effectors of CNV, namely endothelial cells and pericytes. Treating them with ascending doses of Axitinib, cellular angiogenic behaviour under VEGF- and PDGF-stimulation was evaluated in established models of angiogenesis.

Publication II entitled “*Combined VEGF/PDGF inhibition using axitinib induces alphaSMA expression and a pro-fibrotic phenotype in human pericytes*” is designed to evaluate the morphologic and structural changes in the target cell of anti-PDGF, the pericyte, in response to combined anti-VEGF/PDGF inhibition. Treating pericytes with Axitinib, its effects on pericyte cytoskeleton, mRNA and protein expression of pro-fibrotic α-smooth muscle actin (α-SMA) and pro-fibrotic behaviour were evaluated using established models of cellular wound healing.

## 4 Summary

In this *in vitro* model of nAMD, the influence of combined anti-VEGF/PDGF receptor inhibition on endothelial cells and pericytes was investigated. Both cell types are heavily involved in macular neovascularization in nAMD, which, left untreated or managed insufficiently, leads to atrophy and macular subretinal fibrosis, causing end stage subretinal fibrosis and severe vision loss<sup>70,71</sup>. Offering the lowest combined IC<sub>50</sub> for VEGF receptors 1–3 and PDGF receptor  $\beta\beta$ <sup>72</sup>, providing good ocular biocompatibility<sup>72</sup> and being approved by FDA and EMA for the use in humans<sup>69</sup>, the tyrosine kinase inhibitor axitinib was used to assess the impact of anti-VEGF/PDGF on macular neovascularization and fibrotic damage resulting from angiogenesis.

*In vitro*, axitinib reduced VEGF-driven cellular mechanisms of angiogenesis, consisting of endothelial cell migration, ECM adhesion, subsequent proliferation and tube formation, resulting in a 112 % reduction of VEGF-induced tube length. While established anti-VEGF intravitreal therapy with Ranibizumab, Aflibercept or Bevacizumab is already offering these mechanisms of action, about 10-15 % of patients do not show an adequate response to current treatment<sup>20,28,38</sup>. For these patients, Axitinib shows a promising *in vitro* profile as a possible future alternative therapy modulating endothelial cell driven angiogenesis using growth factor receptor inhibition instead of growth factor elimination.

Moreover, axitinib allowed to expand the anti-angiogenetic spectrum beyond anti-VEGF towards PDGF and thus pericyte inhibition. PDGF driven pericyte proliferation and migration were significantly reduced, neutralizing the PDGF stimulated effect – causing a reversion of PDGF directed chemotaxis into a seemingly random chemokinesis, and inhibition of the PDGF driven proliferatory boost. A choroidal neovascularization (CNV) consisting of established endothelial tubes secretes PDGF to attract pericytes, which then in turn stabilize the tubes mechanically and via growth factor secretion<sup>48</sup>. By limiting pericyte proliferation and migration towards the CNV by blocking the PDGF pathway, axitinib might render endothelial cell-only CNV more vulnerable due to the lack of pericyte stabilization, which might prolong anti-VEGF action and force the endothelial tubes into regression. This way, clinical management of patients with nAMD would allow for a step towards CNV ablation instead of constant CNV persistence with constant regrowth after a drop of pharmacological compounds in the vitreous body, which at the moment requires continuous retreatment. Another additive effect of combined anti-VEGF/PDGF therapy observed was the reduction of



fibrovascular-like tissue surrounding endothelial tubes on basement membrane gels (up to -62 %). Scar material in macular fibrosis increases the more fibrovascular tissue a CNV generates; prevention of scarring thus requires a reduction of fibrovascular tissue<sup>71</sup>. As PDGF is a major player in fibrotic processes, from a future clinical perspective Axitinib treatment might reduce the fibrovascular burden accompanying CNV, clearing the subretinal space from debris causing photoreceptor disruption, atrophy, and visual loss<sup>70,71</sup>.

On the contrary, from a clinical perspective the imagination of uncontrolled pericyte ablation might be a threat to the stability of healthy retinal vessels, as pericyte-drop out is a well-known first feature of diabetic microangiopathy<sup>73</sup>. In a second step, we therefore examined the influence of combined anti-VEGF/PDGF inhibition on pericyte morphology, dedifferentiation and cellular function – which is crucial, as steady endogenous PDGF levels are crucial to maintain endothelial-pericyte contact and crosstalk<sup>44</sup>.

After 24 hours, pericytes treated with non-toxic concentrations of axitinib showed an increase in the actin cytoskeleton with focal densities already. As proven on messenger RNA and protein level, this change in phenotype is associated with a significant induction of  $\alpha$ -smooth muscle actin. In other organs of the human body, mainly the lung and kidney, dedifferentiation of pericytes into a similar phenotype has been shown to be an important source of myofibroblasts, driving pathological fibrosis - a mechanism for which  $\alpha$ -SMA upregulation, as in our case, is pathognomonic<sup>51,68,74,75</sup>.

In our model, however, continued anti-VEGF/PDGF inhibition diminished the fibrotic behaviour of these transdifferentiated proto-myofibroblasts, namely scratch wound closure and collagen gel contraction. This might at first sound paradoxical, as migration and contraction are known to be promoted by an induction of contractile fibres of the cytoskeleton<sup>76</sup>. It has been shown, however, that both contraction<sup>77,78</sup> and migration<sup>79,80</sup> depend on signalling via phospholipase  $\gamma$  (PLC- $\gamma$ ), and contraction additionally on protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)<sup>77</sup>. Therefore, continued upstream blockage of PDGF-BB receptors via axitinib seems to diminish the activation of the downstream effectors PLC- $\gamma$ , PKC and PI3K, reducing the fibrotic processes mentioned above in spite of the phenotypic disposition of dedifferentiated pericytes to do so.

Criticism on our study might arise due to the fact that we used a VEGF/PDGF receptor tyrosine kinase inhibitor instead of an antibody or an aptamer, as used pre-clinically<sup>41,54</sup>. We however believe that this was the better choice as axitinib is approved clinically and has been proven effective in inhibiting VEGF and PDGF in humans<sup>64,69</sup>. In addition, it allowed for a more reproducible inhibition of PDGF signalling as PDGF mediating pericyte survival and attachment is secreted in a para/iuxtacrine fashion, and mostly bound to molecules around the pericyte itself, e.g. heparan sulphate proteoglycans; thus, vessel stabilizing, physiological PDGF is difficult to eliminate via antibodies or aptamers in cell culture medium<sup>62</sup>. The importance of this is also supported by the fact that exogenous PDGF *in vivo* does not support pericyte stability, but induces pericyte detachment from maturing vessels, as it is not delivered in the physiological para/iuxtacrine fashion<sup>52</sup>.

In conclusion, this work strengthens the dichotomy of PDGF and PDGF inhibition: As PDGF is strongly involved in vascular formation and maintenance, PDGF inhibition represents a promising new strategy of retinal anti-angiogenesis by targeting pericyte-driven CNV stabilization. As, however, PDGF is pivotal for pericyte survival and differentiation, PDGF inhibition induces pericyte dedifferentiation towards a myofibroblastic phenotype<sup>44,51</sup>. Beyond its involvement in angiogenesis, in this case PDGF signalling takes on its pivotal role in fibrotic mesenchymal responses<sup>62,68,81</sup>. From a future clinical perspective of CNV management in nAMD, anti-PDGF tyrosine kinase activity via axitinib might be capable to reduce pericyte recruitment to growing CNV and strip pericytes off established CNV, rendering CNV more vulnerable to anti-VEGF. Additionally, axitinib might lead to a reduction of perivascular ECM formation around endothelial tubes, probably owing to the function of PDGF as modulator of the ECM<sup>81</sup>. On the other hand, PDGF deprived pericytes might undergo dedifferentiation into proto-myofibroblasts, resulting in an increase of pro-fibrotic cells in the macula<sup>82</sup>. These cells, however, seem to be less prone to fibrosis under continued anti-VEGF/PDGF combination treatment. Therefore, continued anti-VEGF/PDGF activity might be needed beyond its anti-neovascular properties to limit consecutive fibrotic responses. A similar switch between angiogenesis and fibrosis has been described for diabetic retinopathy, termed the 'angiofibrotic switch'<sup>83</sup>.

In summary, pericyte stabilization of CNV is hypothesized to be a major contributor to the high intensity and limited outcomes of state-of-the-art anti-VEGF therapy in nAMD<sup>41,54</sup>. In this context, our *in vitro* data advocate that a combined anti-VEGF/PDGF

intravitreal therapy might improve the management of pathologic neovascularization, prolonging treatment intervals and maybe also offering better long-term visual acuity. Further evidence, including *in vivo* animal studies are definitely needed. Figuratively speaking, however, combined VEGF/PDGF inhibition might offer the opportunity to tackle the CNV by the root, and not to just constantly prune it.

## **5 Zusammenfassung (deutsche Version)**

Anhand eines *in vitro* Zellkulturmodells der neovaskulären AMD (nAMD) wurde in dieser Arbeit untersucht, welchen Einfluss eine kombinierte Inhibition der beiden Wachstumsfaktoren *vascular endothelial growth factor* (VEGF) und *platelet derived growth factor* (PDGF) auf Endothelzellen und Perizyten ausübt. Beide Zelltypen sind verantwortlich für die Bildung makulärer choroidaler Neovaskularisationen (CNV), die unbehandelt zum Endstadium der nAMD, der submakulären Fibrose, und einer daraus resultierenden hochgradigen Sehinderung führen<sup>70,71</sup>. Um den Effekt einer kombinierten VEGF/PDGF-Inhibition auf makuläre Neovaskularisationen und die aus der Angiogenese resultierende Fibrose zu untersuchen, wurde der Tyrosinkinase-Inhibitor Axitinib ausgesucht. Axitinib eignet sich für diese Fragestellung besonders, da diese Substanz die niedrigste klinisch verfügbare mittlere inhibitorische Konzentration (IC<sub>50</sub>) für die VEGF-Rezeptoren 1–3 und den PDGF β-Rezeptor<sup>72</sup> bietet, eine gute okuläre Biokompatibilität aufweist<sup>72</sup>, und nicht zuletzt durch die FDA und EMA für den klinischen Einsatz am Menschen zugelassen ist<sup>69</sup>.

*In vitro* führte Axitinib zu einer signifikanten Reduktion maßgeblicher endothelialer Angiogeneseprozesse, nämlich der Endothelzellmigration, der Adhäsion, Proliferation und Bildung kapillarähnlicher Fortsätze (*tube formation*). Die Länge dieser kapillarähnlichen Fortsätze („*tubes*“), die unter VEGF-Stimulation auf Basalmembran-Gelen untersucht wurde, zeigte sich nach Behandlung mit Axitinib um 112 % reduziert. Obwohl eine ähnliche Wirksamkeit auch von den im klinischen Einsatz befindlichen Substanzen Ranibizumab, Aflibercept und Bevacizumab in solch einem experimentellen Aufbau zu erwarten ist, bieten unsere *in vitro*-Daten Hinweise, dass Axitinib eventuell als Therapiealternative für die 10-15 % der Patienten in Frage käme, die in der Literatur als Non-Responder auf den heutigen Therapiestandard – nämlich reine Wachstumsfaktorinhibition – gelten<sup>20,28,38</sup>. Für diese Patienten zeigt Axitinib ein vielversprechendes *in vitro*-Profil, um die durch Endothelzellen vermittelte Angiogenese nicht nur mittels Wachstumsfaktor-Blockade, sondern mittels entsprechender Rezeptormodulation einzuschränken.

Weiterhin erlaubte es Axitinib als breit wirksamer Tyrosinkinaseinhibitor, das pharmakologische Spektrum der Behandlung für die nAMD über anti-VEGF hinaus zu erweitern. Anders als anti-VEGF-Hemmer im klinischen Einsatz ist Axitinib auch gegen den Wachstumsfaktor PDGF wirksam, der in der Angiogenese ein wichtiges Signalmolekül für Zellen der Gefäßwand, hauptsächlich Perizyten darstellt. Während

der Entstehung einer CNV bilden Endothelzellen zunächst Kapillaren, die in der Folge PDGF sezernieren, um Perizyten zu rekrutieren; diese stabilisieren die neuen Kapillaren mechanisch und mittels Wachstumsfaktorsekretion, um sie damit vor einer Rückbildung durch Entzug von VEGF zu schützen<sup>48</sup>. *In vitro* konnte Axitinib sowohl die PDGF-abhängige Proliferation, als auch Migration der Perizyten erfolgreich inhibieren. Da PDGF den wichtigsten Proliferationsimpuls und das wichtigste Chemokin im Rahmen dieser Rekrutierung von Perizyten Richtung CNV darstellt, könnte Axitinib eventuell auch in Zukunft *in vivo* die gerichtete Chemotaxis zur CNV in eine ungerichtete Chemokinesis umwandeln, und die Zahl der Perizyten auf der sich bildenden CNV deutlich verringern. Somit könnte Axitinib die nur aus Endothelzellen bestehende CNV deutlich anfälliger für anti-VEGF machen, da keine Perizyten-abhängige mechanische und über Wachstumsfaktoren vermittelte Stabilisierung des entstehenden Gefäßes bestünde. Auf diese Weise könnte eine kombinierte anti-VEGF/PDGF-Inhibition in Zukunft eine echte Rückbildung der CNV ermöglichen, während unter Therapie mit den bisherigen anti-VEGF-Substanzen von Perizyten besetzte CNV-Gefäßstümpfe persistieren, aus denen neue Kapillaren sprossen, sobald die anti-VEGF-Wirkspiegel im Glaskörper sinken. Die Notwendigkeit der stetigen Wiederbehandlung könnte somit in Zukunft potentiell vermieden werden.

Als weiterer Zusatznutzen gegenüber anti-VEGF als Monotherapie zeigte sich, dass Axitinib die Menge fibrovaskulären Gewebes um kapilläre endotheliale Strukturen auf Basalmembran-Gelen um bis zu 62 % reduzieren konnte. Um eine makuläre Fibrose zu verhindern, muss die Bildung fibrovaskulären Materials reduziert werden<sup>71</sup>. Da PDGF stark in Signalwege involviert ist, die fibrotisches Material produzieren, könnte Axitinib in Zukunft die Fibrosierung einer CNV reduzieren. Dadurch könnten Photorezeptoren und damit Sehvermögen besser besser erhalten bleiben<sup>70,71</sup>.

Perizyten sind für eine gesunde Netzhautvaskulatur unerlässlich; deshalb ist auf der anderen Seite eine unkontrollierte PDGF-Deprivation retinaler Perizyten an gesunden Gefäßen streng zu vermeiden, da ein Perizytenverlust eines der ersten Zeichen der diabetischen Mikroangiopathie darstellt<sup>73</sup>. Aus diesem Grund untersuchten wir in einem zweiten Schritt, welche Auswirkung eine kombinierte anti-VEGF/PDGF-Inhibition auf die perizytäre Morphologie, Dedifferenzierung und Zellfunktion hatte. Dies ist klinisch hochrelevant, da dauerhafte endogene PDGF-Level vonnöten sind, um die physiologische Zusammenarbeit von Endothelzelle und Perizyten sicherzustellen<sup>44</sup>.

Weniger als 24 Stunden nach einer Behandlung mit nicht-toxischen Dosen von Axitinib zeigte sich in den Perizyten schon eine Induktion des Aktin-Zytoskeletts mit fokalen Zytoskelett-Verdichtungen. Wir konnten auf mRNA- und Proteinebene bestätigen, dass diese Umbauvorgänge mit einer signifikanten Induktion von  $\alpha$ -smooth muscle Aktin ( $\alpha$ SMA) assoziiert sind. In anderen Organen des menschlichen Körpers, hauptsächlich der Lunge und Niere, wurde bereits nachgewiesen, dass solche dedifferenzierte Perizyten eine Hauptquelle von Myofibroblasten darstellen, die zu einer pathologischen, überschüssigen Fibrose führen; für diesen Mechanismus ist eine Hochregulation von  $\alpha$ SMA pathognomonisch<sup>51,68,74,75</sup>.

Trotz dieser Änderung des Phänotyps kam es in den nachfolgenden Zellversuchen zu einer Reduktion pro-fibrotischer Zellmechanismen im *scratch wound*- und Kontraktionsassay. Dies mag zunächst paradox klingen, da beide Mechanismen von einer Hochregulierung kontraktile Fasern begünstigt werden<sup>76</sup>. Es wurde allerdings gezeigt, dass zelluläre Kontraktion<sup>77,78</sup> und Migration<sup>79,80</sup> von der Signalweiterleitung mittels Phospholipase  $\gamma$  (PLC- $\gamma$ ), und Kontraktion alleine zusätzlich von einer Signalweiterleitung mittels Proteinkinase C (PKC) und Phosphoinositide 3-kinase (PI3K) abhängen<sup>77</sup>. Daher ist anzunehmen, dass eine Blockade des PDGF-Signalweges die Aktivierung von PLC- $\gamma$ , PKC und PI3K verringert, was zu einer Reduktion oben genannter fibrotischer Prozesse führt, obwohl die Zellmorphologie sich pro-fibrotisch präsentierte.

An unserer Studie mag zu kritisieren sein, dass wir statt eines präklinischen anti-PDGF-Antikörpers oder Aptamers einen Tyrosinkinase-Inhibitor nutzten<sup>41,55</sup>. Dies ist allerdings dadurch zu rechtfertigen, dass Axitinib bereits zugelassen ist und in anderen *in vitro* Modellen der okulären Angiogenese gut funktioniert<sup>64,69</sup>. Zusätzlich ist zu bedenken, dass das PDGF, das zum Überleben und zur Kommunikation zwischen Endothelzelle und Perizyt beiträgt, para/iuxtakrin sezerniert wird und zu Großteilen an Heparansulfate um den Perizyten gebunden ist; dadurch ist es schwer durch Antikörper oder Aptamere im Zellkulturmedium zu eliminieren<sup>62</sup>. Dies wird auch dadurch bekräftigt, dass *in vivo* exogenes PDGF nicht zur Stabilisierung des Perizyten beiträgt, sondern Perizyten von Gefäßwänden ablöst, da es nicht in der physiologischen para/iuxtakrinen Art sezerniert wird<sup>52</sup>.

Zusammenfassend stärkt unsere Arbeit die Dichotomie von PDGF und PDGF-Inhibition. Da PDGF essentiell für Angiogenese und vaskuläre Homöostase ist,

repräsentiert die PDGF-Inhibition eine vielversprechende Strategie gegen CNV bei nAMD. Da PDGF aber den wichtigsten Wachstumsfaktor für das Überleben und die Differenzierung von Perizyten darstellt, führt eine PDGF-Inhibition zur perizytären Dedifferenzierung in Richtung Myofibroblast<sup>44,51</sup>. In diesem Fall rückt die Rolle von PDGF als Modulator fibrotischer mesenchymaler Gewebereaktionen in den Vordergrund<sup>62,68,81</sup>. In einem möglichen zukünftigen klinischen Einsatz könnte Axitinib über eine zusätzliche PDGF-Inhibition die Rekrutierung von Perizyten zur CNV stoppen, CNV-assoziierte Perizyten von der CNV lösen, und dadurch die CNV intensiver gegenüber anti-VEGF exponieren. Zusätzlich könnte Axitinib die Menge des perivaskulären Gewebes reduzieren, das endotheliale Gewebestrukturen umgibt, da PDGF in seiner Funktion als Modulator der extrazellulären Matrix (ECM) gehemmt wird<sup>81</sup>. Auf der anderen Seite erfolgt als Reaktion auf den pharmakologischen PDGF-Entzug eine Dedifferenzierung der Perizyten in Richtung proto-Myofibroblast, was die pro-fibrotische Zelllast in der Makula erhöht<sup>82</sup>. Wird die anti-VEGF/PDGF-Therapie jedoch fortgeführt, zeigt dieser Zelltyp eine untypischer Weise geringe Aktivierung pro-fibrotischer Zellprozesse. Deshalb könnte die kombinierte anti-VEGF/PDGF-Therapie im klinischen Einsatz über ihre anti-angiogene Funktion hinaus eine große Rolle spielen, um aus Angiogenese resultierende fibrotische Prozesse zu modulieren, wie man es vom 'angiofibrotischen switch' in der diabetischen Retinopathie her kennt<sup>83</sup>. Es ist davon auszugehen, dass die perizytäre Stabilisierung der CNV zur hohen Therapieintensität der derzeitigen anti-VEGF-Therapie und bisher limitierten Langzeit-Visusprognose beiträgt<sup>41,54</sup>. In diesem Zusammenhang machen unsere *in vitro*-Daten Hoffnung, dass Axitinib möglicherweise auch klinisch in Zukunft längere Therapieintervalle und einen besseren Erhalt der Sehfunktion zulassen könnte. Weitere Studien, insbesondere im Tiermodell sind nötig, um die breite Anwendbarkeit weiter zu prüfen. Eine kombinierte VEGF/PDGF-Inhibition könnte jedoch die Möglichkeit bieten, über die Induktion einer vaskulären Regression die CNV kausal zu therapieren, statt nur mit wiederholten Re-Injektionen einen kurzfristigen Effekt auf das erneute Gefäßwachstum auszuüben.

## 6 Publications resulting from this thesis

### I.

Siedlecki J, Wertheimer C, Wolf A, Liegl R, Priglinger C, Priglinger S, Eibl-Lindner, K. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.

*Graefe's Archive for Clinical and Experimental Ophthalmology.*  
2017;255(5):963-972

doi: 10.1007/s00417-017-3595-z



## II.

Siedlecki J, Asani B, Wertheimer C, Hillenmayer A, Ohlmann A, Priglinger C, Priglinger S, Wolf A, Eibl-Lindner K. Combined VEGF/PDGF inhibition using axitinib induces alphaSMA expression and a pro-fibrotic phenotype in human pericytes.

*Graefe's Archive for Clinical and Experimental Ophthalmology.*  
2018;256(6):1141-1149

doi: 10.1007/s00417-018-3987-8

## 7 References

1. Wells-Gray EM, Choi SS, Bries A, Doble N. Variation in rod and cone density from the fovea to the mid-periphery in healthy human retinas using adaptive optics scanning laser ophthalmoscopy. *Eye*. 2016;30(8):1135-1143.
2. Snodderly DM, Sandstrom MM, Leung IY, Zucker CL, Neuringer M. Retinal pigment epithelial cell distribution in central retina of rhesus monkeys. *Invest Ophthalmol Vis Sci*. 2002;43(9):2815-2818.
3. Manjunath V, Taha M, Fujimoto JG, Duker JS. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. *Am J Ophthalmol*. 2010;150(3):325-329.e321.
4. Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, Yamashiro K, Akiba M, Yoshimura N. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2011;52(8):4971-4978.
5. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. *Am J Ophthalmol*. 2009;147(5):811-815.
6. Gao H, Hollyfield JG. Aging of the human retina. Differential loss of neurons and retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci*. 1992;33(1):1-17.
7. Panda-Jonas S, Jonas JB, Jakobczyk-Zmija M. Retinal photoreceptor density decreases with age. *Ophthalmology*. 1995;102(12):1853-1859.
8. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. *Lancet*. 2012;379(9827):1728-1738.
9. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99(6):933-943.
10. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol*. 1980;24(Suppl):335-610.
11. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106-116.
12. Spaide RF. Improving the Age-Related Macular Degeneration Construct: A New Classification System. *Retina*. 2018;38(5):891-899.
13. Wang L, Clark ME, Crossman DK, Kojima K, Messinger JD, Mobley JA, Curcio CA. Abundant Lipid and Protein Components of Drusen. *PLoS One*. 2010;5(4).
14. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. *Surv Ophthalmol*. 1999;44(1):1-29.
15. Ferris FL, 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR. Clinical classification of age-related macular degeneration. *Ophthalmology*. 2013;120(4):844-851.
16. Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. *Arch Ophthalmol*. 1986;104(5):702-705.

17. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. *Arch Ophthalmol.* 1984;102(11):1640-1642.
18. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. *Am J Ophthalmol.* 2001;131(5):541-560.
19. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. *Arch Ophthalmol.* 1999;117(10):1329-1345.
20. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. *New Engl J Med.* 2006;355(14):1419-1431.
21. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *New Engl J Med.* 2006;355(14):1432-1444.
22. Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3<sup>rd</sup>, Fine SL. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology.* 2016;123(8):1751-1761.
23. Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, Fruttiger M. Expression of neonatal Fc receptor in the eye. *Invest Ophthalmol Vis Sci.* 2014;55(3):1607-1615.
24. Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. *Curr Drug Metab.* 2015;16(7):572-584.
25. Joo K, Park SJ, Choi Y, Lee JE, Na YM, Hong HK, Park KH, Kim HM, Chung JY, Woo SJ. Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs. *Invest Ophthalmol Vis Sci.* 2017;58(10):4261-4267.
26. Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, Cousins SW. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. *Am J Ophthalmol.* 2012;153(6):1116-1124.e1111.
27. Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of Real-world Outcomes of Intravitreal Ranibizumab for the Treatment of Age-related Macular Degeneration. *Retina.* 2016;36(8):1418-1431.
28. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. *Ophthalmology.* 2015;122(6):1212-1219.
29. Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Morlet N, Young S, Barthelmes D, Gillies MC. Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. *Ophthalmology.* 2016;123(11):2393-2400.
30. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal

- ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. *Am J Ophthalmol*. 2009;148(1):43-58.e41.
31. Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, Lu C, Katz TA, Schmidt-Erfurth U. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. *Ophthalmology*. 2016;123(7):1521-1529.
  32. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. *Invest Ophthalmol Vis Sci*. 2010;51(1):405-412.
  33. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). *Ophthalmology*. 2013;120(11):2292-2299.
  34. Reich O, Bachmann LM, Faes L, Böhni SC, Bittner M, Howell JP, Thiel MA, Rapold R, Schmid MK. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. *Risk Manag Healthc Policy*. 2015;8:55-62.
  35. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GF, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*. 2012;119(12):2537-2548.
  36. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. *Ophthalmology*. 2014;121(1):193-201.
  37. Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. *PLoS One*. 2015;10(7):e0133968.
  38. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. *Ophthalmology*. 2011;118(3):523-530.
  39. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2004;42(1):91-101.
  40. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. *FASEB J*. 2004;18(2):338-340.
  41. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Monés J, Pearlman JA, Quaranta-EI Maftouhi M, Ricci F, Westby K, Patel SC. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. *Ophthalmology*. 2017;124(2):224-234.

42. Jaffe GJ, Elliott D, Wells JA, Prenner JL, Papp A, Patel S. A Phase 1 Study of Intravitreal E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. *Ophthalmology*. 2016;123(1):78-85.
43. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. *Nature*. 2005;438(7070):967-974.
44. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. *Circ Res*. 2005;97(6):512-523.
45. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. *Cell*. 2011;146(6):873-887.
46. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol*. 2003;161(6):1163-1177.
47. Huang D, Jia Y, Rispoli M, Tan O, Lumbroso B. OCT Angiography of Time Course of Choroidal Neovascularization in Response to Anti-angiogenic Treatment. *Retina*. 2015;35(11):2260-2264.
48. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. *Exp Cell Res*. 2006;312(5):623-629.
49. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. *Blood*. 2011;118(10):2906-2917.
50. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. *Dev Biol*. 2003;264(1):275-288.
51. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell*. 2011;21(2):193-215.
52. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development*. 1998;125(9):1591-1598.
53. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. *Arch Biochem Biophys*. 2002;398(2):284-290.
54. Sadiq MA, Hanout M, Sarwar S, Hassan M, Do DV, Nguyen QD, Sepah YJ. Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. *Saudi J Ophthalmol* 2015;29(4):287-291.
55. Akiyama H, Kachi S, Silva RL, Umeda N, Hackett SF, McCauley D, McCauley T, Zoltoski A, Epstein DM, Campochiaro PA. Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. *J Cell Physiol*. 2006;207(2):407-412.
56. Zehetner C, Kirchmair R, Neururer SB, Kralinger MT, Bechrakis NE, Kieselbach GF. Systemic upregulation of PDGF-B in patients with neovascular AMD. *Invest Ophthalmol Vis Sci*. 2014;55(1):337-344.
57. Novartis AG. Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD). <https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients>. 12th of December 2016 [accessed 8th of June 2018, 18:32]
58. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*. 2004;351(27):2805-2816.

59. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. *Health Technol Assess.* 2008;12(16):iii-iv, ix-201.
60. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. *Br J Ophthalmol.* 2007;91(9):1177-1182.
61. Giddabasappa A, Lalwani K, Norberg R, Gukasyan HJ, Paterson D, Schachar RA, Rittenhouse K, Klamerus K, Mosyak L, Eswaraka J. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models. *Exp Eye Res.* 2016;145:373-379.
62. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. *Genes Dev.* 2008;22(10):1276-1312.
63. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med.* 2003;9(6):669-676.
64. Kelly RJ, Rixe O. Axitinib (AG-013736). *Recent Results Cancer Res.* 2010;184:33-44.
65. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. *Curr Opin Investig Drugs.* 2008;9(6):658-671.
66. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. *J Cell Biol.* 2007;177(3):489-500.
67. Kernt M, Thiele S, Liegl RG, Kernt B, Eibl K, Haritoglou C, Ulbig MW, Kampik A. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. *Growth factors.* 2012;30(1):49-61.
68. Chang FC, Chou YH, Chen YT, Lin SL. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. *J Formos Med Assoc.* 2012;111(11):589-598.
69. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncol.* 2013;14(6):552-562.
70. Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, Maguire MG. Risk of scar in the comparison of age-related macular degeneration treatments trials. *Ophthalmology.* 2014;121(3):656-666.
71. Ishikawa K, Kannan R, Hinton DR. Molecular mechanisms of subretinal fibrosis in age-related macular degeneration. *Exp Eye Res.* 2016;142:19-25.
72. Thiele S, Liegl RG, Konig S, Siedlecki J, Langer J, Eibl K, Haritoglou C, Kampik A, Kernt M. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use]. *Klin Monbl Augenheilkd.* 2013;230(3):247-254.
73. Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: mechanisms and consequences. *Curr Med Chem.* 2013;20(26):3218-3225.
74. Hinz B, Gabbiani G. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. *F1000 Biol Rep.* 2010;2:78.
75. Schimpf C, Duffield JS. Mechanisms of fibrosis: the role of the pericyte. *Curr Opin Nephrol Hypertens.* 2011;20(3):297-305.

76. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. *Biochim Biophys Acta*. 2007;1773(5):642-652.
77. Reyhani V, Tsioumpekou M, van Wieringen T, Rask L, Lennartsson J, Rubin K. PDGF-BB enhances collagen gel contraction through a PI3K-PLC $\gamma$ -PKC-cofilin pathway. *Sci Rep*. 2017;7(1):8924.
78. Ahlén K, Berg A, Stiger F, Tengholm A, Siegbahn A, Gylfe E, Reed RK, Rubin K. Cell interactions with collagen matrices in vivo and in vitro depend on phosphatidylinositol 3-kinase and free cytoplasmic calcium. *Cell Adh Commun*. 1998;5(6):461-473.
79. Harper L, Kashiwagi Y, Pusey CD, Hendry BM, Domin J. Platelet-derived growth factor reorganizes the actin cytoskeleton through 3-phosphoinositide-dependent and 3-phosphoinositide-independent mechanisms in human mesangial cells. *Nephron Physiol*. 2007;107(2):p45-56.
80. Hooshmand-Rad R, Claesson-Welsh L, Wennstrom S, Yokote K, Siegbahn A, Heldin CH. Involvement of phosphatidylinositide 3'-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. *Exp Cell Res*. 1997;234(2):434-441.
81. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. *Cytokine Growth Factor Rev*. 2004;15(4):255-273.
82. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. *Rheumatology (Oxford)*. 2008;47 Suppl 5:v2-4.
83. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. *PLoS One*. 2008;3(7):e2675.

## **8 Acknowledgment**

I would like to thank Prof. Dr. med. Kirsten Eibl-Lindner for providing the opportunity to conduct this research, always generously handing over knowledge and ideas, encouraging me to think beyond the present state of evidence and guiding me with the clinical implication of our findings.

I would also like to thank Dr. med. Christian Wertheimer, who introduced me to the art of laboratory research, provided me with unlimited support in theoretical, practical, technical and abstract problems and who always was a source of inspiration and motivation.

Moreover, I want so to say a big thank you to my laboratory team. Working together at usual and unusual hours has always been a big pleasure!

This work would not have been possible without the love of my family, consisting of my parents Dr. med. Dr. med. habil. Jerzy Siedlecki and Dr. med. Katharina Siedlecki, my grandmother Marie von Dehn-Ordo, my brother Martin Siedlecki, and my partner Aniela Dadas, who have always been an unlimited source of support.



## 9 Curriculum vitae



Jakob Siedlecki

Tel.: +49 89 4400-53811

Email: jakob.siedlecki@med.uni-muenchen.de

### CURRICULUM VITAE

---

#### Person

Nationality: German

---

#### School Education

2008 High School graduation from Gymnasium bei St. Stephan, Augsburg (final grade: „very good: 1.0“)

---

#### Studies and professional training

2008 – 2010 Medical Studies at Ludwig Maximilians-University, Munich  
2010 – 2015 Medical Studies at Technical University, Munich  
07/2015 Medical license, graduating from Technical University Munich (final grade: „very good: 1.16“)  
since 09/2015 Resident in Ophthalmology at the University Eye Hospital Munich

---

#### Professional societies

2014 Association for Research in Vision and Ophthalmology (ARVO)  
since 2016 German Ophthalmological Society (DOG)  
since 2017 European Society of Cataract and Refractive Surgeons (ESCRS)

---

#### Training abroad

08/2011 Landspítali University Hospital, Reykjavík, Island  
09 – 12/2014 Inselspital University Hospital, Bern, Switzerland

### **Research (please also see the publication list attached)**

---

- since 04/2013 Experimental research at the Laboratory of cellular biology,  
University Eye Clinic Munich
- since 09/2015 Clinical research (anterior segment and retina) at the University  
Eye Clinic Munich and the SMILE Eyes Clinic Linz, Austria
- since 2017 Reviewer for *Journal of Ophthalmology*, *Microcirculation*,  
*European Journal of Ophthalmology*

### **Awards and Scholarships**

---

- 02/2017 Best Presentation Award of the *German Society for Intraocular  
Lens Implantology (DGII)*
- 2016 – 2017 *Friedrich Baur Foundation* Research Grant for the in-vitro  
evaluation of combined endothelial cell/pericyte inhibition for  
neovascular AMD
- 06/2016 Travel Grant of the *German Retina Society*
- 2008 – 2015 Full study scholarship of the *German National Merit Foundation*  
(„Studienstiftung des deutschen Volkes“)
- 2008 – 2015 Full study scholarship of the *Bavarian Merit Foundation*  
(„Max Weber-Programm“)

## 10 Publication list

### A) Publications with peer review

1. **Siedlecki J**, Luft N, Keidel L, Mayer WJ, Kreutzer TC, Priglinger SG, Archer TJ, Reinstein DZ, Dirisamer M. Variation of lenticule thickness for SMILE in Low Myopia. *Journal of refractive surgery*. 2018;34(7):453-459
2. Luft N, Schumann RG, Dirisamer M, Kook D, **Siedlecki J**, Wertheimer C, Priglinger SG, Mayer WJ. Wound Healing, Inflammation, and Corneal Ultrastructure After SMILE and Femtosecond Laser-Assisted LASIK: A Human Ex Vivo Study. *Journal of refractive surgery*. 2018;34(6):393-399.
3. Wertheimer C, Kueres A, **Siedlecki J**, Braun C, Kassumeh S, Wolf A, Mayer W, Priglinger C, Priglinger S, Eibl-Lindner K. The intraocular lens as a drug delivery device for an epidermal growth factor-receptor inhibitor for prophylaxis of posterior capsule opacification. *Acta Ophthalmologica*. 2018. doi: 10.1111/aos.13759. [Epub ahead of print]
4. **Siedlecki J**, Asani B, Wertheimer C, Hillenmayer A, Ohlmann A, Priglinger C, Priglinger S, Wolf A, Eibl-Lindner K. Combined VEGF/PDGF inhibition using axitinib induces alphaSMA expression and a pro-fibrotic phenotype in human pericytes. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2018;256(6):1141-1149
5. **Siedlecki J**, Luft N, Mayer WJ, Siedlecki M, Kook D, Meyer B, Bechmann M, Wiltfang R, Priglinger SG, Dirisamer M. CIRCLE Enhancement After Myopic SMILE. *Journal of refractive surgery*. 2018;34(5):304-309.
6. Luft N, **Siedlecki J**, Sekundo W, Wertheimer C, Kreutzer TC, Mayer WJ, Priglinger SG, Dirisamer M. Small incision lenticule extraction (SMILE) monovision for presbyopia correction. *European journal of ophthalmology*. 2018;28(3):287-293.
7. Schumann RG, Vogt D, Haritoglou C, Hagenau F, **Siedlecki J**, Wolf A, Priglinger SG. [Histopathological correlation of epiretinal tissue in lamellar macular holes and macular pseudoholes]. *Der Ophthalmologe*. 2017;114(12):1110-1116.
8. **Siedlecki J**, Luft N, Kook D, Wertheimer C, Mayer WJ, Bechmann M, Wiltfang R, Priglinger SG, Sekundo W, Dirisamer M. Enhancement after myopic small incision lenticule extraction (SMILE) using surface ablation. *Journal of refractive surgery*. 2018;33(8):513-518
9. **Siedlecki J**, Mackert MM, Wolf A, Berking C, Priglinger SG, Eibl-Lindner K. Bilateral visual field defects in a patient treated with Trametinib and Dabrafenib for melanoma of unknown origin. *Retinal Cases and Brief Reports*. 2017 Apr [Epub ahead of print]
10. **Siedlecki J**, Reiterer V, Leicht S, Foerster S, Kortüm K, Schaller U, Priglinger SG, Fuerweger C, Muacevic A, Eibl-Lindner K. Incidence of secondary

glaucoma after treatment of uveal melanoma with robotic radiosurgery versus brachytherapy. *Acta Ophthalmologica*. 2017;95(8):e734-e739.

11. **Siedlecki J**, Wertheimer C, Wolf A, Liegl R, Priglinger C, Priglinger S, Eibl-Lindner, K. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2017;255(5):963-972
12. Wertheimer C, **Siedlecki J**, Kook D, Mayer W, Wolf A, Klingenstein A, Kampik A, Eibl-Lindner K: EGF-Receptor Inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2015;253(3): 409-17
13. Liegl R, Koenig S, **Siedlecki J**, Haritoglou C, Kampik A, Kernt M: Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression. *PLoS One*. 2014 Feb 26;9(2): e88203.
14. Thiele S, Liegl RG, König S, **Siedlecki J**, Langer J, Eibl K, Haritoglou C, Kampik A, Kernt M: [Multikinase-Inhibitors as new therapy option in neovascular AMD: In-vitro evaluation of the intravitreal safety-profile of Axitinib, Pazopanib and Sorafenib]. *Klinische Monatsblätter für Augenheilkunde*. 2013; 230(3): 247-254

#### B) Citeable conference abstracts

1. EURETINA 2018, Vienna  
**Siedlecki J**, Vounotrypidis E, Vogt D, F. Hagenau F, Wolf A, Priglinger S, Schumann R: Simultaneous MacTel type 1 and lamellar hole associated epiretinal proliferation detected by multimodal imaging
2. WORLD OPHTHAMOLOGY CONFERENCE 2018, Barcelona  
**Siedlecki J**, Luft N, Priglinger S, Dirisamer M: CIRCLE enhancement after myopic small incision lenticule extraction (SMILE)
3. ESCRS 2017, Lisbon  
**Siedlecki J**, Luft N, Kook D, Luft N, Wiltfang R, Dirisamer M: Enhancement after myopic small incision lenticule extraction (SMILE) using surface ablation.
4. EURETINA 2016, Copenhagen  
**Siedlecki J**, Wertheimer C, Wolf A, Alge-Priglinger C, Priglinger SG, Eibl-Lindner EK: Axitinib exerts anti-angiogenic properties on human endothelial cells and pericytes in an in vitro-model of nAMD via combined VEGF and PDGF tyrosine kinase inhibition.
5. GERMAN OPHTHALMOLOGICAL SOCIETY 2015, BERLIN  
**Siedlecki J**, Wertheimer C, Liegl R, Kernt M, Kampik A, Eibl-Lindner EK: [The pericyte as new target in anti-neovascular therapy: Inhibition of proliferation and migration of human pericytes after treatment with the tyrosine kinase inhibitor Axitinib]

6. WORLD OPHTHAMOLOGY CONFERENCE 2014, TOKYO  
**Siedlecki J**, Liegl R, Kernt M, Arend N, Kampik A: Axitinib Inhibits Vascular Endothelial Growth Factor (VEGF) Expression and Secretion and Modulates Anti-VEGF Induced Dysregulation of VEGF/Connective Tissue Growth Factor (CTGF) Ratio in Human Retinal Pigment-Epithelium and Vascular Endothelial Cells

C) Publications for magazines without peer review

1. **Siedlecki J**. Evaluating Corneal Refractive Options for Presbyopic Patients: Efficacy and Patient Satisfaction. *EuroTimes Supplement*, September 2018
2. **Siedlecki J**. SMILE monovision – an effective and safe treatment for presbyopic ametropic patients. *Ophthalmology Times*, August 2018
3. **Siedlecki J**. [Nachkorrektur nach myoper SMILE mittels PRK]. *DGII Aktuell*, October 2017
4. **Siedlecki J**, Luft N, Dirisamer M. [Advanced Triple Procedure: DMEK bei komplexen Vorderabschnittspathologien]. *Der Augenspiegel*, October 2017
5. **Siedlecki J**. [Fibrosis and atrophy: still unsolved long-term complications of neovascular AMD]. *Ophthalmologische Nachrichten*, April 2017
6. **Siedlecki J**, Schumann RG. [Paradigm shift in neovascular AMD]. *Ophthalmologische Nachrichten*, April 2017